The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
TLR agonists: our best frenemy in cancer immunotherapy
Open accessAbstract
Review on the ability of different TLR agonists to orchestrate antitumor immune responses, or promote tumor growth, underscoring the impact of choosing among TLR agonists when applying these therapies in the clinic. Various TLR agonists are currently under investigation in clinical trials for their ability to orchestrate antitumor immunity. The antitumor responses are largely attributed to their aptitude to stimulate APCs such as DCs which in turn, activate tumor-specific T cell responses. However, there is a potential for TLR signaling to occur on cells other than professional APCs that could negate antitumor responses or even worse, promote tumor growth. The impetus for this review is twofold. First, there is accumulating data demonstrating that the engagement of TLRs on different T cell subsets and different cancer types could promote tumor growth or conversely, contribute to antitumor responses. Second, the efficacy of TLR agonists as monotherapies to treat cancer patients has been limited. In this review, we discuss how TLR signaling within different T cell subsets and cancer cells can potentially impact the generation of antitumor responses. Based on evidence from preclinical models and clinical trials, we draw attention to several criteria that we believe must be considered when selecting TLR agonists for developing effective immunotherapeutic strategies against cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zanin-Zhorov, A., Nussbaum, G., Franitza, S., Cohen, I. R., & Lider, O. (2003) · The FASEB Journal · doi:10.1096/fj.02-1139fje · Cited by 187
RetractedTolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Toll-like receptors and innate immunity
Medzhitov, R. (2001) · Nature Reviews Immunology · doi:10.1038/35100529 · Cited by 4,308
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Kaech, S. M., Tan, J. T., Wherry, E. J., Konieczny, B. T., Surh, C. D., & Ahmed, R. (2003) · Nature Immunology · doi:10.1038/ni1009 · Cited by 1,830 · cited 2×
“The costimulatory effects of TLR signaling are associated with increased PI3K and PKC signaling [40, 66].”
BackgroundOncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Negative regulation of Toll-like receptor-mediated immune responses
Liew, F. Y., Xu, D., Brint, E. K., & O'Neill, L. A. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1630 · Cited by 1,509
Inferences, questions and possibilities in Toll-like receptor signalling
Beutler, B. (2004) · Nature · doi:10.1038/nature02761 · Cited by 1,466
Li, A., Dubey, S., Varney, M. L., Dave, B. J., & Singh, R. K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3369 · Cited by 1,332
Progress in human tumour immunology and immunotherapy
Rosenberg, S. A. (2001) · Nature · doi:10.1038/35077246 · Cited by 1,325
Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., & Lanzavecchia, A. (2005) · Nature Immunology · doi:10.1038/ni1223 · Cited by 1,157
Identity of tumour necrosis factor and the macrophage-secreted factor cachectin
Beutler, B., Greenwald, D., Hulmes, J. D., Chang, M., Pan, Y.-C. E., Mathison, J., Ulevitch, R., & Cerami, A. (1985) · Nature · doi:10.1038/316552a0 · Cited by 1,131
Regulatory T Cells Selectively Express Toll-like Receptors and Are Activated by Lipopolysaccharide
Caramalho, I., Lopes-Carvalho, T., Ostler, D., Zelenay, S., Haury, M., & Demengeot, J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021633 · Cited by 970
COLEY, W. B. (1991) · PubMed · Cited by 965
Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells
Sato, K., Ozaki, K., Oh, I., Meguro, A., Hatanaka, K., Nagai, T., Muroi, K., & Ozawa, K. (2007) · Blood · doi:10.1182/blood-2006-02-002246 · Cited by 954
High mobility group box 1 protein interacts with multiple Toll-like receptors
Park, J. S., Gamboni-Robertson, F., He, Q., Svetkauskaite, D., Kim, J.-Y., Strassheim, D., Sohn, J.-W., Yamada, S., Maruyama, I., Banerjee, A., et al. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00401.2005 · Cited by 932
Toll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2
Biragyn, A., Ruffini, P. A., Leifer, C. A., Klyushnenkova, E., Shakhov, A., Chertov, O., Shirakawa, A. K., Farber, J. M., Segal, D. M., Oppenheim, J. J., et al. (2002) · Science · doi:10.1126/science.1075565 · Cited by 902
Targeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
Human Toll-Like Receptors Mediate Cellular Activation by Mycobacterium tuberculosis
Means, T. K., Wang, S., Lien, E., Yoshimura, A., Golenbock, D. T., & Fenton, M. J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.7.3920 · Cited by 804
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Ristimaki, A. P., Sivula, A., Lundin, J. E., Lundin, M., Salminen, T. M., Haglund, C. H., Joensuu, H., & Isola, J. J. (2002) · PubMed · Cited by 780
Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-6
Jones, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.3463 · Cited by 771
Toll-like receptor 2 controls expansion and function of regulatory T cells
Sutmuller, R. P. M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25439 · Cited by 756
Toll-Like Receptor 8-Mediated Reversal of CD4 + Regulatory T Cell Function
Peng, G., Guo, Z., Kiniwa, Y., Voo, K. S., Peng, W., Fu, T., Wang, D. Y., Li, Y., Wang, H. Y., & Wang, R.-F. (2005) · Science · doi:10.1126/science.1113401 · Cited by 746
Toll‐like receptors and adaptor molecules in liver disease: Update†
Seki, E., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.22306 · Cited by 722 · cited 2×
“In addition to the synthetic TLR1-TLR2 agonists, bacterial lipoprotein has been reported to increase antigen-specific tumor killing by CD8 T cells, in in vitro and in vivo models [54, 55].”
BackgroundMidwood, K., Sacre, S., Piccinini, A. M., Inglis, J., Trebaul, A., Chan, E., Drexler, S., Sofat, N., Kashiwagi, M., Orend, G., et al. (2009) · Nature Medicine · doi:10.1038/nm.1987 · Cited by 703
Programmed contraction of CD8+ T cells after infection
Badovinac, V. P., Porter, B. B., & Harty, J. T. (2002) · Nature Immunology · doi:10.1038/ni804 · Cited by 578
Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance
Huang, B., Zhao, J., Li, H., He, K.-L., Chen, Y., Mayer, L., Unkeless, J. C., & Xiong, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0784 · Cited by 542
Geisse, J., Caro, I., Lindholm, J., Golitz, L., Stampone, P., & Owens, M. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.11.066 · Cited by 505
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9793 · Cited by 487
TLR2 is expressed on activated T cells as a costimulatory receptor
Komai-Koma, M., Jones, L., Ogg, G. S., Xu, D., & Liew, F. Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400171101 · Cited by 483
TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells
Salaun, B., Coste, I., Rissoan, M.-C., Lebecque, S. J., & Renno, T. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4894 · Cited by 479
Dillon, S., Agrawal, A., Van Dyke, T., Landreth, G., McCauley, L., Koh, A., Maliszewski, C., Akira, S., & Pulendran, B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4733 · Cited by 460
Redecke, V., Häcker, H., Datta, S. K., Fermin, A., Pitha, P. M., Broide, D. H., & Raz, E. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2739 · Cited by 448
Toll-like receptor 2 signaling modulates the functions of CD4 + CD25 + regulatory T cells
Liu, H., Komai-Koma, M., Xu, D., & Liew, F. Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601554103 · Cited by 440
Hasan, U., Chaffois, C., Gaillard, C., Saulnier, V., Merck, E., Tancredi, S., Guiet, C., Brière, F., Vlach, J., Lebecque, S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2942 · Cited by 435
Jocham, D., Richter, A., Hoffmann, L., Iwig, K., Fahlenkamp, D., Zakrzewski, G., Schmitt, E., Dannenberg, T., Lehmacher, W., von Wietersheim, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15590-6 · Cited by 434
Caron, G., Duluc, D., Frémaux, I., Jeannin, P., David, C., Gascan, H., & Delneste, Y. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1551 · Cited by 410
Tsuji, S., Matsumoto, M., Takeuchi, O., Akira, S., Azuma, I., Hayashi, A., Toyoshima, K., & Seya, T. (2000) · Infection and Immunity · doi:10.1128/iai.68.12.6883-6890.2000 · Cited by 409
Peng, G., Wang, H. Y., Peng, W., Kiniwa, Y., Seo, K. H., & Wang, R.-F. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.020 · Cited by 408
Toll-Like Receptor Ligands Directly Promote Activated CD4+ T Cell Survival
Gelman, A. E., Zhang, J., Choi, Y., & Turka, L. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6065 · Cited by 386
Crellin, N. K., Garcia, R. V., Hadisfar, O., Allan, S. E., Steiner, T. S., & Levings, M. K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.8051 · Cited by 375
Ahonen, C. L., Doxsee, C. L., McGurran, S. M., Riter, T. R., Wade, W. F., Barth, R. J., Vasilakos, J. P., Noelle, R. J., & Kedl, R. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031591 · Cited by 362
He, W., Liu, Q., Wang, L., Chen, W., Li, N., & Cao, X. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.01.022 · Cited by 340
Flagellin Promotes Myeloid Differentiation Factor 88-Dependent Development of Th2-Type Response
Didierlaurent, A., Ferrero, I., Otten, L. A., Dubois, B., Reinhardt, M., Carlsen, H., Blomhoff, R., Akira, S., Kraehenbuhl, J.-P., & Sirard, J.-C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6922 · Cited by 310
Toll-Like Receptor Agonists in Cancer Therapy
Adams, S. (2009) · Immunotherapy · doi:10.2217/imt.09.70 · Cited by 310
Chouaib, S., Welte, K., Mertelsmann, R., & Dupont, B. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.2.1172 · Cited by 307
Reynolds, J. M., Pappu, B. P., Peng, J., Martinez, G. J., Zhang, Y., Chung, Y., Ma, L., Yang, X. O., Nurieva, R. I., Tian, Q., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.010 · Cited by 299
Heat Shock Proteins as Ligands of Toll-Like Receptors
Vabulas, R. M., Wagner, H., & Schild, H. (2002) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59430-4_11 · Cited by 276
Seki, E., Tsutsui, H., Tsuji, N. M., Hayashi, N., Adachi, K., Nakano, H., Futatsugi-Yumikura, S., Takeuchi, O., Hoshino, K., Akira, S., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3863 · Cited by 272
Hoover, H. C., Brandhorst, J. S., Peters, L. C., Surdyke, M. G., Takeshita, Y., Madariaga, J., Muenz, L. R., & Hanna, M. G. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.390 · Cited by 259
The role of interleukin-8 in cancer cells and microenvironment interaction
Yuan, A. (2005) · Frontiers in Bioscience · doi:10.2741/1579 · Cited by 252
Harmey, J. H., Bucana, C. D., Lu, W., Byrne, A. M., McDonnell, S., Lynch, C., Bouchier‐Hayes, D., & Dong, Z. (2002) · International Journal of Cancer · doi:10.1002/ijc.10632 · Cited by 247
Warger, T., Osterloh, P., Rechtsteiner, G., Fassbender, M., Heib, V., Schmid, B., Schmitt, E., Schild, H., & Radsak, M. P. (2006) · Blood · doi:10.1182/blood-2005-10-4015 · Cited by 242
Cherfils-Vicini, J., Platonova, S., Gillard, M., Laurans, L., Validire, P., Caliandro, R., Magdeleinat, P., Mami-Chouaib, F., Dieu-Nosjean, M.-C., Fridman, W.-H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci36551 · Cited by 237
Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation
Reynolds, J. M., Martinez, G. J., Chung, Y., & Dong, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120585109 · Cited by 234
Adams, S., Kozhaya, L., Martiniuk, F., Meng, T.-C., Chiriboga, L., Liebes, L., Hochman, T., Shuman, N., Axelrod, D., Speyer, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1149 · Cited by 222
Sequence Variants ofToll-Like Receptor 4Are Associated with Prostate Cancer Risk
Zheng, S. L., Augustsson-Bälter, K., Chang, B., Hedelin, M., Li, L., Adami, H.-O., Bensen, J., Li, G., Johnasson, J.-E., Turner, A. R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3280 · Cited by 219
Proietti, E., Bracci, L., Puzelli, S., Di Pucchio, T., Sestili, P., De Vincenzi, E., Venditti, M., Capone, I., Seif, I., De Maeyer, E., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.375 · Cited by 218
Cai, Z., Sanchez, A., Shi, Z., Zhang, T., Liu, M., & Zhang, D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1993 · Cited by 214
Wang, Y., Niu, X. L., Qu, Y., Wu, J., Zhu, Y. Q., Sun, W. J., & Li, L. Z. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.019 · Cited by 210
Schmaußer, B., Andrulis, M., Endrich, S., Müller-Hermelink, H.-K., & Eck, M. (2005) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2005.02.009 · Cited by 208
Toll-like Receptor 3 Expressed by Melanoma Cells as a Target for Therapy?
Salaun, B., Lebecque, S., Matikainen, S., Rimoldi, D., & Romero, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0274 · Cited by 204
de Gruijl, T. D., van den Eertwegh, A. J. M., Pinedo, H. M., & Scheper, R. J. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0536-z · Cited by 201
Cutting Edge: TLR2 Directly Triggers Th1 Effector Functions
Imanishi, T., Hara, H., Suzuki, S., Suzuki, N., Akira, S., & Saito, T. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6715 · Cited by 200
TLR4‐mediated skin carcinogenesis is dependent on immune and radioresistant cells
Mittal, D., Saccheri, F., Vénéreau, E., Pusterla, T., Bianchi, M. E., & Rescigno, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.94 · Cited by 192
TLR2 engagement on CD8 T cells lowers the thresholdfor optimal antigen‐induced T cell activation
Cottalorda, A., Verschelde, C., Marçais, A., Tomkowiak, M., Musette, P., Uematsu, S., Akira, S., Marvel, J., & Bonnefoy‐Berard, N. (2006) · European Journal of Immunology · doi:10.1002/eji.200636181 · Cited by 190
Robinson, R. A., DeVita, V. T., Levy, H. B., Baron, S., Hubbard, S. P., & Levine, A. S. (1976) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/57.3.599 · Cited by 189
Yang, H., Zhou, H., Feng, P., Zhou, X., Wen, H., Xie, X., Shen, H., & Zhu, X. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-92 · Cited by 187
Zhu, Q., Egelston, C., Gagnon, S., Sui, Y., Belyakov, I. M., Klinman, D. M., & Berzofsky, J. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39293 · Cited by 186
Zhu, Q., Egelston, C., Vivekanandhan, A., Uematsu, S., Akira, S., Klinman, D. M., Belyakov, I. M., & Berzofsky, J. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805325105 · Cited by 183
Rhee, S. H., Im, E., & Pothoulakis, C. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.022 · Cited by 183
Listeria monocytogenes Promotes Tumor Growth via Tumor Cell Toll-Like Receptor 2 Signaling
Huang, B., Zhao, J., Shen, S., Li, H., He, K.-L., Shen, G.-X., Mayer, L., Unkeless, J., Li, D., Yuan, Y., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4067 · Cited by 182
Toll‐like receptors’ two‐edged sword: when immunity meets apoptosis
Salaun, B., Romero, P., & Lebecque, S. (2007) · European Journal of Immunology · doi:10.1002/eji.200737744 · Cited by 179
Role of Toll-like receptors in gastrointestinal malignancies
Fukata, M., & Abreu, M. T. (2008) · Oncogene · doi:10.1038/sj.onc.1210908 · Cited by 178
Manegold, C., Gravenor, D., Woytowitz, D., Mezger, J., Hirsh, V., Albert, G., Al-Adhami, M., Readett, D., Krieg, A. M., & Leichman, C. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5807 · Cited by 171
Grinberg-Bleyer, Y., Saadoun, D., Baeyens, A., Billiard, F., Goldstein, J. D., Grégoire, S., Martin, G. H., Elhage, R., Derian, N., Carpentier, W., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42945 · Cited by 167
Sequence Variants of Toll-Like Receptor 4 and Susceptibility to Prostate Cancer
Chen, Y.-C., Giovannucci, E., Lazarus, R., Kraft, P., Ketkar, S., & Hunter, D. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2078 · Cited by 167
A Novel Toll-like Receptor That Recognizes Vesicular Stomatitis Virus
Shi, Z., Cai, Z., Sanchez, A., Zhang, T., Wen, S., Wang, J., Yang, J., Fu, S., & Zhang, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.159590 · Cited by 165
dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8
Estornes, Y., Toscano, F., Virard, F., Jacquemin, G., Pierrot, A., Vanbervliet, B., Bonnin, M., Lalaoui, N., Mercier-Gouy, P., Pachéco, Y., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2012.22 · Cited by 164
Direct Costimulatory Effect of TLR3 Ligand Poly(I:C) on Human γδ T Lymphocytes
Wesch, D., Beetz, S., Oberg, H.-H., Marget, M., Krengel, K., & Kabelitz, D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1348 · Cited by 162
(1943) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/4.1.81 · Cited by 162
Chang, Y., Wu, M., Lin, J., & Chen, C. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.8242 · Cited by 158
Uehori, J., Matsumoto, M., Tsuji, S., Akazawa, T., Takeuchi, O., Akira, S., Kawata, T., Azuma, I., Toyoshima, K., & Seya, T. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4238-4249.2003 · Cited by 156
CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells
Bendigs, S., Salzer, U., Lipford, G. B., Wagner, H., & Heeg, K. M. (1999) · European Journal of Immunology · Cited by 153
Role of urothelial cells in BCG immunotherapy for superficial bladder cancer
Bevers, R. F. M., Kurth, K. H., & Schamhart, D. H. J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602026 · Cited by 149
Lu, H., Yang, Y., Gad, E. A., Wenner, C. A., Chang, A. E., Larson, E. R., Dang, Y., Martzen, M. R., Standish, L. J., & Disis, M. L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1763 · Cited by 147
Zhang, Y., Luo, F., Cai, Y., Liu, N., Wang, L., Xu, D., & Chu, Y. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002320 · Cited by 145
The application of Toll like receptors for cancer therapy
So, E. Y., & Ouchi, T. (2010) · International Journal of Biological Sciences · doi:10.7150/ijbs.6.675 · Cited by 144
The contribution of direct TLR signaling to T cell responses
Rahman, A. H., Taylor, D. K., & Turka, L. A. (2009) · Immunologic Research · doi:10.1007/s12026-009-8113-x · Cited by 143
TLR4 signaling in effector CD4+ T cells regulates TCR activation and experimental colitis in mice
González-Navajas, J. M., Fine, S., Law, J. K., Datta, S. K., Nguyen, K. P., Yu, M., Corr, M., Katakura, K., Eckmann, L., Lee, J., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40055 · Cited by 143
KUNDU, S. D., Lee, C., Billips, B. K., Habermacher, G. M., Zhang, Q., Liu, V., Wong, L. Y., Klumpp, D. J., & Thumbikat, P. (2007) · The Prostate · doi:10.1002/pros.20710 · Cited by 139
The biological paths of IL-1 family members IL-18 and IL-33
Smith, D. E. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0810470 · Cited by 135
Structure of the activating IL-1 receptor signaling complex
Thomas, C., Bazán, J. F., & García, K. C. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2260 · Cited by 135
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
Houot, R., Goldstein, M. J., Kohrt, H. E. K., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., Irish, J. M., Torchia, J. A., Kolstad, A., Chen, L., et al. (2009) · Blood · doi:10.1182/blood-2009-05-223958 · Cited by 135
Human Effector CD8+ T Lymphocytes Express TLR3 as a Functional Coreceptor
Tabiasco, J., Devêvre, E., Rufer, N., Salaun, B., Cerottini, J., Speiser, D. E., & Romero, P. J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8708 · Cited by 135
I. The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas
COLEV, W. B. (1893) · Annals of Surgery · doi:10.1097/00000658-189307000-00009 · Cited by 134
Kuai, W. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i9.979 · Cited by 134
Anticancer function of polyinosinic-polycytidylic acid
Cheng, Y., & Xu, F. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.12.13450 · Cited by 131
Engineering Dendritic Cells to Enhance Cancer Immunotherapy
Boudreau, J. E., Bonehill, A., Thielemans, K., & Wan, Y. (2011) · Molecular Therapy · doi:10.1038/mt.2011.57 · Cited by 131
Li, J., Song, W., Czerwinski, D. K., Varghese, B., Uematsu, S., Akira, S., Krieg, A. Μ., & Levy, R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2493 · Cited by 125
Kutikhin, A. G. (2011) · Human Immunology · doi:10.1016/j.humimm.2011.07.307 · Cited by 123
Quigley, M. M., Martinez, J., Huang, X., & Yang, Y. (2008) · Blood · doi:10.1182/blood-2008-03-148809 · Cited by 121
Babu, S., Blauvelt, C. P., Kumaraswami, V., & Nutman, T. B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.7.3885 · Cited by 118
Toriseva, M., Laato, M. K., Carpén, O., Ruohonen, S. T., Savontaus, E., Inada, M., Krane, S. M., & Kähäri, V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042596 · Cited by 117
T cell expression of MyD88 is required for resistance to Toxoplasma gondii
LaRosa, D. F., Stumhofer, J. S., Gelman, A. E., Rahman, A. H., Taylor, D. K., Hunter, C. A., & Turka, L. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706663105 · Cited by 111
Conforti, R., Ma, Y., Morel, Y., Paturel, C., Terme, M., Viaud, S., Ryffel, B., Ferrantini, M., Uppaluri, R., Schreiber, R. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1890 · Cited by 111
Pachathundikandi, S. K., Brandt, S., Madassery, J. V., & Backert, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019614 · Cited by 108
Mercier, B. C., Cottalorda, A., Coupet, C., Marvel, J., & Bonnefoy, N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801167 · Cited by 103
Microsatelite GT polymorphism in the toll‐like receptor 2 is associated with colorectal cancer
Jelavić, T. B., Barišić, M., Hofman, I. D., Perica, V. B., Vrdoljak, E., Peruzović, M., Hozo, I., Puljiz, Ž., & Terzić, J. (2006) · Clinical Genetics · doi:10.1111/j.1399-0004.2006.00651.x · Cited by 100
Midgley, R. S., McConkey, C. C., Johnstone, E. C., Dunn, J., Smith, J. L., Grumett, S. A., Julier, P., Iveson, C., Yanagisawa, Y., Warren, B. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6244 · Cited by 100
Thuringer, D., Hammann, A., Benikhlef, N., Fourmaux, E., Bouchot, A., Wettstein, G., Solary, É., & Garrido, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.154823 · Cited by 98
Role of toll-like receptors in tissue repair and tumorigenesis
Rakoff-Nahoum, S., & Medzhitov, R. M. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908050088 · Cited by 92
Chochi, K., Ichikura, T., Kinoshita, M., Majima, T., Shinomiya, N., Tsujimoto, H., Kawabata, T., Sugasawa, H., Ono, S., Seki, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4467 · Cited by 89
Geng, D., Zheng, L., Srivastava, R., Asprodites, N., Velasco‐Gonzalez, C., & Dávila, E. (2010) · Blood · doi:10.1182/blood-2010-02-268169 · Cited by 88
ADJUVANT TREATMENT WITH POLYADENYLIC-POLYURIDYLIC ACID (POLYA.POLYU) IN OPERABLE BREAST CANCER
Lacour, J., Spira, A., Petit, J., Sarrazin, D., Lacour, F., Michelson, M., Delage, G. L., Contesso, G., & Viguier, J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)90057-4 · Cited by 86
Sobek, V., Birkner, N., Falk, I. J., Würch, A., Kirschning, C. J., Wagner, H., Wallich, R., Lamers, M. C., & Simon, M. M. (2004) · Arthritis Research & Therapy · doi:10.1186/ar1212 · Cited by 86
Govindaraj, R. G., Manavalan, B., Lee, G., & Choi, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012713 · Cited by 85
Salem, M. L., Diaz-Montero, C. M., El-Naggar, S. A., Chen, Y., Moussa, O., & Cole, D. J. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.11.013 · Cited by 85
Samara, K. D., Antoniou, K. M., Karagiannis, K., Μαργαριτόπουλος, Γ., Lasithiotaki, I., Koutala, E., & Siafakas, N. M. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1374 · Cited by 84
Millrud, C. R., Månsson, A., Uddman, R., et al. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.03041.x · Cited by 84
Bauer, A. K., Dixon, D., DeGraff, L. M., Cho, H., Walker, C. R., Malkinson, A. M., & Kleeberger, S. R. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji403 · Cited by 84
Mal Mediates TLR-Induced Activation of CREB and Expression of IL-10
Mellett, M., Atzei, P., Jackson, R. P., O'Neill, L. A. J., & Moynagh, P. N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002739 · Cited by 82
McCarron, M. J., & Reen, D. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.55 · Cited by 80
Augmentation of Therapeutic Responses in Melanoma by Inhibition of IRAK-1,-4
Srivastava, R., Geng, D., Liu, Y., Zheng, L., Li, Z., Joseph, M. A., McKenna, C., Bansal, N., Ochoa, A. C., & Dávila, E. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0337 · Cited by 80
Rahman, A. H., Cui, W., LaRosa, D. F., Taylor, D. K., Zhang, J., Goldstein, D. R., Wherry, E. J., Kaech, S. M., & Turka, L. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3804 · Cited by 78
Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma
Brignole, C., Marimpietri, D., Paolo, D. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1251 · Cited by 77
Asprodites, N., Zheng, L., Geng, D., Velasco‐Gonzalez, C., Sanchez-Perez, L. A., & Dávila, E. (2008) · The FASEB Journal · doi:10.1096/fj.08-108274 · Cited by 77
Regulation of naïve and memory T-cell homeostasis
Surh, C. D., & Sprent, J. (2002) · Microbes and Infection · doi:10.1016/s1286-4579(01)01509-x · Cited by 76
TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients
Wang, C., Cao, S., Yan, Y., Ying, Q., Jiang, T., Xu, K., & Wu, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-415 · Cited by 75
Lancioni, C., Li, Q., Thomas, J. J., Ding, X., Thiel, B., Drage, M. G., Pecora, N., Ziady, A. G., Shank, S. L., Harding, C. V., et al. (2010) · Infection and Immunity · doi:10.1128/iai.00806-10 · Cited by 75
Deetz, C. O., Hebbeler, A. M., Propp, N., Cairo, C., Tikhonov, I. I., & Pauza, C. D. (2006) · Infection and Immunity · doi:10.1128/iai.00088-06 · Cited by 75
Human gastric cancer development with TNF-α-inducing protein secreted from Helicobacter pylori
Suganuma, M., Watanabe, T., Yamaguchi, K., Takahashi, A., & Fujiki, H. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.027 · Cited by 74
Stone, G. W., Barzee, S., Snarsky, V., Santucci, C., Tran, B., Langer, R., Zugates, G. T., Anderson, D. G., & Kornbluth, R. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007334 · Cited by 72
Increased Expression of Toll-like Receptors (TLR) 2, 4 and 5 in Gastric Dysplasia
Pimentel‐Nunes, P., Afonso, L. P., Lopes, P., Roncon‐Albuquerque, R., Gonçalves, N., Henrique, R., Moreira‐Dias, L., Leite-Moreira, A. F., & Dinis-Ribeiro, M. J. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9368-9 · Cited by 70
Marsland, B. J., Nembrini, C., Grün, K., Reissmann, R., Kurrer, M. O., Leipner, C., & Köpf, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3466 · Cited by 69
TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis
Taura, M., Fukuda, R., Suico, M. A., Eguma, A., Koga, T., Shuto, T., Sato, T., Morino‐Koga, S., & Kai, H. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01567.x · Cited by 69
Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5
Park, J.-H. (2011) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2011.656 · Cited by 69
Baars, A., Claessen, A. M. E., van den Eertwegh, A. J. M., Gall, H. E., Stam, A. G. M., Meijer, S., Giaccone, G., Meijer, C. J. L. M., Scheper, R. J., Wagstaff, J., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008363601515 · Cited by 69
Kucera, K., Koblansky, A. A., Saunders, L. P., Frederick, K. B., Cruz, E. M. D. L., Ghosh, S., & Modis, Y. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.09.022 · Cited by 68
Shiraki (1992) · International Journal of Oncology · doi:10.3892/ijo_00000080 · Cited by 67
Direct recognition of LPS by human but not murine CD8+ T cells via TLR4 complex
Komai‐Koma, M., Gilchrist, D. S., & Xu, D. (2009) · European Journal of Immunology · doi:10.1002/eji.200838866 · Cited by 63
Expression of Toll-Like Receptors on Breast Tumors: Taking a Toll on Tumor Microenvironment
Bhattacharya, D., & Yusuf, N. (2011) · International Journal of Breast Cancer · doi:10.1155/2012/716564 · Cited by 63
TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help
Hervás‐Stubbs, S., Olivier, A., Boisgérault, F., Thiéblemont, N., & Leclerc, C. (2007) · Blood · doi:10.1182/blood-2006-10-053256 · Cited by 63
The Adaptor Molecule MyD88 Directly Promotes CD8 T Cell Responses to Vaccinia Virus
Zhao, Y., Trez, C. D., Flynn, R., Ware, C. F., Croft, M., & Salek‐Ardakani, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803682 · Cited by 62
Davis, M. B., Vasquez-Dunddel, D., Fu, J. L., Albesiano, E., Pardoll, D., & Kim, Y. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3262 · Cited by 61
Toll-Like Receptors in Normal and Malignant Human Bladders
Ayari, C., Bergeron, A., LaRue, H., Ménard, C., & Fradet, Y. (2011) · The Journal of Urology · doi:10.1016/j.juro.2010.12.097 · Cited by 60
Chiron, D., Pellat‐Deceunynck, C., Amiot, M., Bataille, R., & Jégo, G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803113 · Cited by 59
JANSSON, O. T., Morcos, E., Brundin, L., Lundberg, J. O., Adolfsson, J., Söderhäll, M., & Wiklund, P. N. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.545 · Cited by 59
Fávaro, W. J., Nunes, O. D. S., Seiva, F. R. F., Nunes, I. D. S., Woolhiser, L. K., Durán, N., & Lenaerts, A. J. M. (2012) · Infectious Agents and Cancer · doi:10.1186/1750-9378-7-14 · Cited by 57
Anticancer TLR agonists on the ropes
Guha, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3775 · Cited by 53
Scharf, S., Hippenstiel, S., Flieger, A., Suttorp, N., & N’Guessan, P. D. (2010) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00365.2009 · Cited by 52
Chiffoleau, E., Heslan, J., Heslan, M., Louvet, C., Condamine, T., & Cuturi, M. C. (2006) · International Immunology · doi:10.1093/intimm/dxl136 · Cited by 52
Down‐regulation of CXCR4 expression on human CD8+ T cells during peripheral differentiation
Kobayashi, N., Takata, H., Yokota, S., & Takiguchi, M. (2004) · European Journal of Immunology · doi:10.1002/eji.200425587 · Cited by 48
Pellegrini, P., Contasta, I., Beato, T. D., Ciccone, F., & Berghella, A. M. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/819724 · Cited by 47
Huang, Y., Cai, B., Xu, M., Qiu, Z., Tao, Y., Zhang, Y., Wang, J., Xu, Y., Zhou, Y., Yang, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038890 · Cited by 46
Geng, D., Zheng, L., Srivastava, R., Velasco‐Gonzalez, C., Riker, A. I., Markovic, S. N., & Dávila, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0247 · Cited by 46
Zheng, L., Asprodites, N., Keene, A. H., Rodríguez, P. C., Brown, K. D., & Dávila, E. (2007) · Blood · doi:10.1182/blood-2007-07-104141 · Cited by 45
Clemens, E. B., Zeng, W., Doherty, P. C., Jackson, D. C., Kedzierska, K., & Turner, S. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2187 · Cited by 41
Laplanche, A., Alzieu, L., Delozier, T., Berlie, J., Veyret, C., Fargeot, P., Luboinski, M., & Lacour, J. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006498121628 · Cited by 40
Mitchell, D., Yong, M. C. R., Schroder, W. A., Black, M., Tirrell, M., & Olive, C. (2010) · The Journal of Infectious Diseases · doi:10.1086/653499 · Cited by 39
SNAPIN: an endogenous toll-like receptor ligand in rheumatoid arthritis
Shi, B., Huang, Q.-Q., Tak, P. P., Vervoordeldonk, M. J., Huang, C., Dorfleutner, A., Stehlik, C., & Pope, R. M. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200899 · Cited by 39
Reactive Oxygen Species Enhance TLR10 Expression in the Human Monocytic Cell Line THP-1
Kim, D. H., Kim, Y. J., Koh, H. S., Jang, T. Y., Park, H. E., & Kim, J. Y. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms11103769 · Cited by 38
Effects of LPS-mediated bystander activation in the innate immune system
Yadav, R., Zammit, D. J., Lefrançois, L., & Vella, A. T. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0406253 · Cited by 30
Rudilla, F., Fayolle, C., Casares, N., Durántez, M., Arribillaga, L., Lozano, T., Villanueva, L., Pío, R., Sarobe, P., Leclerc, C., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.02.052 · Cited by 29
Mueller, K. L., Daniëls, M. A., Felthauser, A. M., Kao, C., Jameson, S. C., & Shimizu, Y. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2222 · Cited by 29
Toll-Like Receptors as Novel Therapeutic Targets for Ovarian Cancer
Muccioli, M., Sprague, L., Nandigam, H., Pate, M., & Benencia, F. (2012) · ISRN Oncology · doi:10.5402/2012/642141 · Cited by 27
Bartholdy, C., Christensen, J. E., Grujić, M., Christensen, J. P., & Thomsen, A. R. (2009) · Journal of General Virology · doi:10.1099/vir.0.004960-0 · Cited by 27
Salem, M. L. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.02.019 · Cited by 21
Triozzi, P. L., Aldrich, W. A., & Ponnazhagan, S. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.54 · Cited by 20
Effects of Toll-Like Receptor Signals in T-Cell Neoplasms
Morrison, C., Baer, M. R., Zandberg, D. P., Kimball, A. S., & Dávila, E. (2011) · Future Oncology · doi:10.2217/fon.10.185 · Cited by 11
Cited by
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 714
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
Metadata
- Authors
- Kaczanowska, S., Joseph, A. M., & Davila, E.
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-03-08
- Volume
- 93
- Issue
- 6
- Pages
- 847-863
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2123662098
- Cited by
- 339
- References
- 179
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.